Maze Therapeutics MAZE
NASDAQ MAZE
$36.73 +1.28 (+3.61%)
As of: Nov 11, 2026 · 3:58 PM EST

Maze Therapeutics (MAZE) Return on Sales [ROS] (2024 - 2026)

Updated

Maze Therapeutics (MAZE) reported Return on Sales [ROS] of -728.06% for Q2 2026, up 4305.14 percentage points from -5033.20% a year earlier but down 595.30 percentage points from the prior quarter.

Analysis

Maze Therapeutics (MAZE) Return on Sales [ROS] (2024 - 2026) Analysis & Trends

For FY2024, Maze Therapeutics posted Return on Sales [ROS] of 34.38%.

  • Five-year quarterly Return on Sales [ROS] spans a low of -5033.20% in Q2 2025 and a high of 84.58% in Q2 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Maze Therapeutics 2.00 Bn 506.07 Mn - -820.82%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -820.82%
Jun 30, 2026 -728.06%
Mar 31, 2026 -132.77%
Jun 30, 2025 -5,033.20%
Mar 31, 2025 29.97%
Sep 30, 2024 -969.16%
Jun 30, 2024 84.58%
API Access

Maze Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=MAZE&period=max&api_key=YOUR_API_KEY